Component of Oligomeric Golgi Complex 6–Congenital Disorder of Glycosylation (COG6-CDG)

Component of oligomeric Golgi complex 6–congenital disorder of glycosylation (short name COG6-CDG) is a very rare genetic disease that affects how sugar chains are added to proteins in the body. These sugar chains are called glycans, and the whole process is called glycosylation. The COG6 gene gives the body instructions to make one part (subunit 6) of a larger group of proteins called the conserved oligomeric Golgi (COG) complex. This complex works inside the Golgi apparatus, which is like a sorting and packing center in each cell. It helps move proteins and put the correct sugar chains on them.

Component of oligomeric Golgi complex 6–congenital disorder of glycosylation (COG6-CDG, also called conserved oligomeric Golgi complex subunit 6 deficiency or CDG type IIL) is a very rare, inherited genetic disease. It happens when both copies of the COG6 gene have harmful variants. The COG6 protein is part of the conserved oligomeric Golgi (COG) complex, which helps move and process proteins and fats inside the Golgi apparatus. When COG6 does not work, sugar chains (glycans) are attached to proteins in the wrong way, a problem called a congenital disorder of glycosylation (CDG). This leads to multi-system disease affecting the brain, muscles, liver, hormones, bones, skin and growth. Only a few dozen patients have been reported worldwide, and symptoms can vary a lot from child to child.

Children with COG6-CDG often have poor growth, low muscle tone, developmental delay or intellectual disability, seizures, feeding problems, digestive issues, recurrent infections, abnormal fat distribution, and sometimes hormone or genital differences. Some babies have serious complications in early life, and in severe cases the condition can be life-limiting. There is no current cure or specific COG6-targeted medicine, so care focuses on treating symptoms, supporting development, preventing complications and helping the family over time.

When both copies of the COG6 gene have harmful changes (mutations), the COG6 protein does not work well. The Golgi cannot place sugar chains on many proteins in the normal way. Because these proteins are important in almost every organ, many body systems can be affected, such as the brain, liver, gut, blood, skin, heart, and immune system.

COG6-CDG usually starts in the newborn period or early infancy. Babies often have poor growth, weak muscles (hypotonia), delayed development, feeding problems, and repeated infections. Many children also have liver and gut problems and sometimes blood and bleeding problems. In many reported cases the disease is severe, but milder cases are now being described as more patients are found.

Other names

Doctors and researchers use several names for this same condition. These names all point to COG6-CDG:

1. COG6-congenital disorder of glycosylation

2. COG6-CDG

3. CDG type IIL or CDG-IIL

4. CDG2L (another code for type 2L)

5. Congenital disorder of glycosylation type 2L

6. Shaheen syndrome (a name used in some early families)

7. Historically, it belongs to the group once called “carbohydrate-deficient glycoprotein syndromes”, the old name for CDG disorders.

These different names can be confusing, but they all describe the same genetic disease caused by harmful changes in the COG6 gene.

Types

There is not a formal medical system that divides COG6-CDG into official type 1, type 2, etc. However, from the small number of patients reported, doctors can see several patterns of how the disease appears. These are “clinical forms,” not strict official subtypes:

1. Severe early-onset form
   In this form, signs start before birth or soon after birth. Babies may have poor growth in the womb, low muscle tone, breathing problems, strong feeding problems, big liver, and serious blood and infection problems. Some babies die in infancy or early childhood because many organs are affected.

2. Classic infantile multisystem form
   This is the pattern described in many case reports. Babies have poor growth, developmental delay, hypotonia, liver and gut problems, repeated infections, and sometimes heart or bone differences. They survive longer than the most severe cases but have long-term disability.

3. Milder childhood-onset form
   Newer reports show some children with milder features, such as moderate developmental delay, smaller growth problems, and fewer life-threatening complications. These children may still have serious needs but can live longer and may reach more skills than those with the severe form.

4. Form with prominent skin and skeletal features
   Some patients show striking skin findings (for example, reduced sweating or thick skin) and bone changes like extra fingers or toes. These features highlight how important glycosylation is for skin and bone development.

Because the condition is extremely rare (fewer than a few dozen patients reported worldwide), doctors expect that more clinical forms will be described as new cases are found.

Causes

Remember: the main cause is always a genetic mutation in the COG6 gene. The items below explain that main cause and related mechanisms or risk factors in simple steps.

1. Harmful mutation in the COG6 gene
   The direct cause of COG6-CDG is a harmful change (mutation) in both copies of the COG6 gene. This change stops the gene from making a normal COG6 protein.

2. Autosomal recessive inheritance
   The disease is autosomal recessive. This means a child gets one mutated copy from each parent. The parents usually do not have symptoms because they still have one working copy of the gene.

3. Missense mutations
   A missense mutation changes one “letter” in the gene code and swaps one amino acid in the protein. If this happens at an important spot, the COG6 protein cannot work properly.

4. Nonsense mutations
   A nonsense mutation turns a normal amino-acid code into a “stop” signal. This makes a very short, broken COG6 protein that is usually destroyed by the cell and cannot do its job.

5. Frameshift mutations
   Small insertions or deletions (adding or removing DNA letters) can shift the reading frame of the gene. This also creates a faulty protein, leading to loss of function of COG6.

6. Splice-site mutations
   Some mutations happen at places that control how the gene is cut and joined (splicing). Wrong splicing can remove or add parts of the COG6 message, which again leads to an abnormal protein.

7. Large deletions in COG6
   A bigger deletion can remove a whole section of the gene. This stops production of normal COG6 protein completely in that copy. If both copies are affected, the disease appears.

8. Loss of COG6 protein stability
   Even if the protein is made, some mutations make it unstable. The cell may break down the weak COG6 protein faster than normal, leaving too little to support normal Golgi function.

9. Disrupted COG complex assembly
   COG6 is one part of the multi-subunit COG complex. When COG6 is faulty or missing, the whole complex may not build correctly. This affects trafficking of many proteins inside the Golgi.

10. Mis-positioning of glycosylation enzymes
    In a healthy Golgi, enzymes that add sugar chains are placed in exact positions. In COG6-CDG, the COG complex cannot guide these enzymes properly, so proteins receive the wrong sugar pattern or not enough sugar.

11. Defective N-glycosylation of many proteins
    Because enzymes and trafficking are disturbed, N-glycosylation (adding sugar chains to certain asparagine sites on proteins) is abnormal in many tissues. This global problem explains why so many organs are affected.

12. Abnormal glycosylation of coagulation proteins
    Some blood clotting proteins need proper sugar chains to work. Faulty glycosylation can cause a tendency to bleed or have clotting problems in COG6-CDG.

13. Abnormal glycosylation of immune proteins
    Antibodies and other immune proteins also need correct glycosylation. Changes here can weaken the immune response and contribute to repeated infections.

14. Abnormal glycosylation of liver and gut proteins
    Many liver and intestinal proteins are glycoproteins. When they are not built correctly, children can develop liver enlargement, raised liver enzymes, and gut problems such as diarrhea and protein loss.

15. Abnormal glycosylation in the brain
    Brain development depends on many glycoproteins. Their abnormal glycosylation can slow brain growth, cause microcephaly (small head size), seizures, and learning problems.

16. Consanguinity (parents related by blood)
    In several families, the parents were related (for example, cousins). When parents share some ancestors, they are more likely to carry the same rare mutation, so the chance for an affected child is higher.

17. Founder variants in certain populations
    In some regions, one specific COG6 mutation may be shared by several unrelated families (a founder variant). This can lead to more cases in that population, even though the disease is still very rare worldwide.

18. Random chance in carriers
    Even without consanguinity, two healthy carriers can meet by chance and have a child with COG6-CDG if both pass on their mutated copy. This is a matter of genetic chance, not lifestyle or behavior.

19. No known environmental cause
    There is no evidence that infections, medicines, diet, or toxins cause COG6-CDG by themselves. These factors might change how sick a child feels but they do not create the underlying gene mutation.

20. New (de novo) mutations (rare)
    In theory, a new mutation could appear in the sperm or egg, even if no parent is a carrier. This seems very rare, but it is a possible cause in some families without a family history.

Symptoms

Symptoms differ between children, even with the same mutation, but some features are seen often.

1. Poor growth and failure to thrive
   Many babies do not gain weight or length as expected. They may have trouble feeding, vomit often, or lose nutrients through the gut, so they stay small and thin for their age.

2. Developmental delay
   Children may sit, stand, walk, and talk later than other children. Some may never reach full independence. Both motor skills and learning are often affected.

3. Low muscle tone (hypotonia)
   Babies can feel “floppy” when held, and their head may lag behind. As they grow, they may have weak muscles and tire easily when moving.

4. Microcephaly (small head size)
   Many children have a head that is smaller than expected for age and sex. This usually reflects slower brain growth and may be linked with developmental problems.

5. Liver problems
   The liver may be enlarged (hepatomegaly), and blood tests may show raised liver enzymes. In some children there can be problems with making proteins or clotting factors.

6. Gastrointestinal problems
   Diarrhea, vomiting, feeding difficulty, and protein-losing enteropathy (loss of protein through the gut) can occur. These problems contribute to poor growth and low blood protein.

7. Recurrent infections
   Many children have repeated chest infections, ear infections, or other bacterial or viral illnesses. This may be related to abnormal glycosylation of immune system proteins.

8. Blood and bone-marrow abnormalities
   Some patients have low platelets, anemia, or even low levels of several blood cell types. This can cause easy bruising, tiredness, and greater risk of infection.

9. Bleeding tendency
   Because clotting factors can be affected, children may bruise easily, have nosebleeds, or bleed longer from cuts or medical procedures.

10. Skin problems
    Reports describe reduced sweating (hypohidrosis), unusual thickening of the skin (hyperkeratosis), or other skin changes. These features show how glycosylation affects skin structure and sweat glands.

11. Facial and skeletal differences
    Some children have subtle facial differences and limb changes, such as extra fingers or toes (post-axial polydactyly) or other bone anomalies. These are not always present but can give doctors clues.

12. Heart problems
    A few patients have heart defects such as septal defects (holes between chambers). These may cause breathing problems or poor feeding, especially in infants.

13. Seizures (in some patients)
    Not all, but some children develop epileptic seizures. These can be hard to control and usually show that the brain is strongly affected.

14. Temperature and sweating problems
    Some children do not sweat normally or have trouble regulating body temperature. This can lead to overheating in hot weather or during fever.

15. Genital and organ malformations (in some cases)
    Rarely, boys have ambiguous genitalia (for example, small penis, undescended testes) or bowel malrotation. These rare findings suggest that glycosylation also affects sex development and gut positioning.

Diagnostic tests

Because COG6-CDG affects many organs, diagnosis usually needs several kinds of tests. Doctors first suspect a CDG from the clinical picture, then confirm it with special blood tests and genetic tests.

Physical exam tests

1. General physical examination
   The doctor checks weight, length, head size, growth charts, facial features, skin, and overall appearance. Poor growth, small head, unusual facial features, and skin changes can suggest a CDG, including COG6-CDG.

2. Neurological examination
   The doctor looks at muscle tone, strength, reflexes, posture, and coordination. Low muscle tone, delayed milestones, and abnormal reflexes point to a neurological problem often seen in CDG.

3. Abdominal examination
   By gently feeling the abdomen, the doctor checks for an enlarged liver or spleen, abdominal tenderness, or fluid. Liver enlargement with growth and development problems can support suspicion of COG6-CDG.

4. Cardiac and respiratory examination
   Listening to the heart and lungs can detect heart murmurs or breathing difficulties. Heart defects or frequent chest infections may be part of the overall picture.

Manual / bedside tests

5. Developmental screening tests
   Simple tools and checklists help measure when a child sits, walks, and speaks. Clear delay in many areas suggests a global developmental problem, which is common in COG6-CDG.

6. Muscle tone and strength testing
   The doctor moves the child’s arms and legs and asks older children to push and pull. Very floppy or weak muscles support the diagnosis of a neuromuscular disorder like CDG.

7. Gait and coordination assessment
   If the child can stand or walk, the doctor watches balance, walking pattern, and coordination. Unsteady gait or ataxia may be seen in some CDG patients.

8. Simple vision and hearing checks
   Bedside tests, such as following a light or reacting to sound, give a first idea of vision and hearing. More formal tests may be done later if needed. Problems here are not specific but add to the general picture.

Laboratory and pathological tests

9. Complete blood count (CBC)
   This common blood test measures red cells, white cells, and platelets. In COG6-CDG, there may be anemia, low platelets, or low levels of several blood cell types, helping explain bleeding or infection problems.

10. Liver function tests
    Blood tests such as AST, ALT, GGT, and bilirubin show how well the liver is working. Many COG6-CDG patients have raised liver enzymes or other signs of liver stress.

11. Coagulation profile
    Tests like PT, aPTT, and clotting factor levels look at blood clotting. Abnormal results can explain easy bruising and bleeding and are common in CDG disorders.

12. Serum proteins and albumin
    These tests measure total protein and albumin in the blood. Low levels may occur if the liver cannot make enough protein or if protein is lost through the gut, as seen in some CDG patients.

13. Transferrin glycoform analysis (CDG screening test)
    This special blood test looks at how sugar chains are attached to transferrin, a protein made in the liver. In many CDG types, including COG6-CDG, the transferrin pattern is abnormal. This is a key screening test for suspected CDG.

14. Detailed glycan or glycoprotein analysis
    In specialized labs, more advanced methods (such as mass spectrometry) study sugar chains on different proteins. These tests give a more detailed picture of the glycosylation defect and help distinguish between CDG types.

15. Genetic testing for COG6 mutations
    Genetic testing (by gene panel, exome, or genome sequencing) can identify harmful changes in the COG6 gene. Finding two disease-causing mutations confirms the diagnosis of COG6-CDG.

Electrodiagnostic tests

16. Electroencephalogram (EEG)
    An EEG records brain electrical activity with small electrodes on the scalp. It is used if seizures or abnormal movements occur. In some children with CDG, EEG may show epileptic activity.

17. Nerve conduction studies and electromyography (EMG)
    These tests measure how fast and how well nerves and muscles carry electrical signals. They can help explain low muscle tone or weakness and rule out other neuromuscular diseases.

18. Electrocardiogram (ECG)
    An ECG records the electrical activity of the heart. It looks for rhythm problems or effects of structural heart defects that sometimes accompany CDG.

Imaging tests

19. Brain MRI
    MRI scans give detailed pictures of the brain. In some CDG types, doctors see cerebellar atrophy, delayed myelination, or other brain changes. Brain MRI helps assess the extent of neurological involvement.

20. Abdominal ultrasound and echocardiogram
    An abdominal ultrasound is used to look at the liver, spleen, and gut for enlargement or structural changes. An echocardiogram uses ultrasound to view heart structure and function. These tests help evaluate organ involvement in COG6-CDG.

Non-pharmacological treatments

1. Multidisciplinary care coordination
   A core non-drug treatment for COG6-CDG is coordinated care. A metabolic specialist, neurologist, gastroenterologist, endocrinologist, physiotherapist, occupational and speech therapists, dietitian, and social worker work together. The purpose is to make sure all problems (feeding, seizures, growth, learning, behaviour, mobility) are addressed with one shared plan. The mechanism is practical: regular joint reviews reduce missed problems, prevent duplicated tests, and help families navigate complex medical systems more easily.

2. Physiotherapy (physical therapy)
   Physiotherapy is used to improve muscle tone, strength, posture and balance in children with low tone, weakness or movement problems. The purpose is to help the child sit, stand, walk or transfer more safely, and to prevent joint contractures and scoliosis. The mechanism is repeated guided movement, stretching and strengthening, which stimulates muscles and nerves and keeps joints flexible. Regular home exercises between sessions help maintain gains and reduce pain or stiffness.

3. Occupational therapy (OT)
   Occupational therapists focus on daily activities such as feeding, dressing, writing, and play. The purpose is to make the child as independent as possible at home and school. The mechanism includes task-specific practice, adapting tools (special cups, utensils, splints), and modifying the environment to match the child’s abilities. OT can also address sensory issues (for example, sensitivity to noise or touch) by structured desensitisation and sensory diets.

4. Speech and language therapy
   Speech therapists help with speech, understanding, and safe swallowing. The purpose is better communication, less frustration, and prevention of choking or aspiration. They use exercises to strengthen mouth and throat muscles, teach alternative communication (pictures, sign, communication devices) and recommend safe food textures if swallowing is weak. This works by building neural pathways for language and coordinating breathing, chewing and swallowing.

5. Nutritional support and high-calorie feeding
   Many children with COG6-CDG have poor weight gain, vomiting, or reflux. A dietitian can design high-calorie feeds, special formulas or thickened feeds to reduce vomiting. The purpose is to improve growth, immunity and strength. The mechanism is simple: giving more calories, protein, vitamins and minerals in forms the child can tolerate, sometimes using continuous feeds or overnight feeds to reduce fatigue and reflux.

6. Feeding strategies and positioning therapy
   Simple physical strategies can reduce reflux and aspiration. The purpose is to keep food moving downwards and stop acid and milk coming back up. The mechanism includes feeding in an upright position, keeping the child upright for 30–45 minutes after feeds, smaller frequent feeds instead of large ones, and adjusting sleep positions according to medical advice. These steps use gravity and slower stomach filling to reduce reflux and choking risk.

7. Respiratory physiotherapy
   Children with weak muscles or swallowing problems can struggle to clear mucus and may get chest infections. Chest physiotherapy uses gentle percussion, vibration, breathing exercises and coughing techniques to move secretions. The purpose is to prevent pneumonia and improve oxygen levels. The mechanism is mechanical mobilisation of mucus plus training in deep breathing and assisted coughing, which keeps airways clearer.

8. Orthotic devices and positioning aids
   Braces, splints, special seating systems and standing frames are non-drug tools to support posture and joint alignment. The purpose is to prevent contractures, hip dislocation and scoliosis, and to allow safer sitting and standing. These devices work by holding joints in safer positions for long periods, reducing abnormal muscle pulls and promoting more typical bone growth and weight bearing.

9. Early intervention and developmental therapy
   Early childhood programmes that mix play-based physical, cognitive and social activities help maximise brain development. The purpose is to support milestones—rolling, sitting, first words, social interaction—at the child’s own pace. The mechanism is neuroplasticity: repeated stimulation of brain pathways strengthens connections, which is especially important in conditions that affect brain development, such as COG6-CDG.

10. Augmentative and alternative communication (AAC)
    When speech is limited, communication boards, symbol cards, eye-gaze devices or tablets with voice output can be introduced. The purpose is to give the child a “voice” for needs, choices and feelings. The mechanism is bypassing weak speech muscles and using stronger skills (vision, pointing, eye movement) to form messages, which can reduce behaviour problems caused by frustration.

11. Psychological and social support for families
    Living with an ultra-rare, complex condition is emotionally and financially stressful. Counselling, support groups, and contact with CDG family organisations can help. The purpose is to reduce anxiety, depression and isolation. The mechanism is emotional support, shared knowledge, and practical advice about rights, benefits and care systems, which can improve coping and decision making.

12. Genetic counselling and reproductive planning
    Because COG6-CDG is autosomal recessive, parents are usually carriers. Genetic counselling explains inheritance, carrier testing for relatives, and options for future pregnancies (such as prenatal or preimplantation genetic diagnosis where available). The purpose is informed choice and realistic expectations. The mechanism is education about recurrence risks and available tests, helping families plan time and pregnancy care safely.

13. Educational support and individualised learning plans
    Children with COG6-CDG may need special education services, classroom aides or adapted materials. The purpose is to match teaching methods to the child’s cognitive and motor abilities. The mechanism is structured support—small-group teaching, visual aids, extra time, breaking tasks into steps—which can improve learning, attention and social skills.

14. Vision and hearing rehabilitation
    Some children have strabismus, visual impairment or hearing loss. Regular eye and hearing checks, glasses, patching, hearing aids or cochlear implants may be needed. The purpose is to maximise sensory input for learning and safety. The mechanism is improving signal quality to the brain so it can process information more effectively, which helps communication and development.

15. Dental and oral-motor therapy
    Oral-motor exercises, good dental care and regular dentist visits are important, especially if there is drooling, teeth grinding or feeding difficulty. The purpose is to prevent cavities, gum disease and aspiration, and to improve chewing. The mechanism is strengthening mouth muscles, improving saliva control and maintaining healthy teeth to support eating and speech.

16. Structured sleep routines and sleep hygiene
    Children with neurologic disorders often have sleep problems. Regular sleep schedules, calming bedtime routines, reduced screens before bed and comfortable sleep environments can help. The purpose is better sleep quality for the child and caregivers. The mechanism is stabilising the body’s internal clock and reducing arousal, which supports mood, behaviour and seizure control.

17. Infection control and hygiene practices
    Because some children may be more prone to infections, practical steps like regular handwashing, up-to-date vaccines, avoiding sick contacts when possible and good oral care can help. The purpose is to reduce hospitalisations and serious illnesses. The mechanism is lowering exposure to germs and supporting the immune system’s ability to cope with infections.

18. Palliative and supportive care in severe cases
    For children with very severe disease and life-limiting complications, palliative care teams can support symptom control and family decisions. The purpose is to improve comfort and respect family goals, not to stop treatment. The mechanism is careful pain and symptom assessment, advance care planning, and emotional support, coordinated with the primary team.

19. Regular structured monitoring and care plans
    Written care plans with scheduled checks for growth, nutrition, liver function, heart, hormones and development help detect problems early. The purpose is prevention or early treatment of complications. The mechanism is standardised follow-up intervals and test panels, which reduce the chance that important issues will be missed in this complex condition.

20. Family education and emergency plans
    Teaching families about seizure first aid, feeding risks, dehydration and when to call emergency services is crucial. The purpose is rapid response to serious symptoms. The mechanism is simple: written emergency letters, action plans and training help caregivers recognise danger signs and communicate clearly with healthcare providers, improving safety.

---

Drug treatments

Important note: No medicine currently fixes the basic COG6 glycosylation defect. All drugs listed below are general supportive options used for problems such as seizures, reflux, spasticity or constipation in many neurological and metabolic diseases. Exact drug choice and dose must always be decided by the treating doctor using official labels and the child’s individual situation; this is not personal medical advice or a prescription.

1. Levetiracetam (Keppra)
   Levetiracetam is a broad-spectrum anti-seizure medicine often used in children with difficult epilepsy, including CDGs. It belongs to the antiepileptic drug class and is usually given by mouth (liquid or tablets) two times per day, with dose adjusted to weight and kidney function. It works by binding synaptic vesicle protein SV2A and stabilising neuronal firing. Common side effects include irritability, mood change, sleepiness and dizziness, so behaviour and mood should be monitored.

2. Divalproex sodium / valproic acid (Depakote, Depakote ER)
   Valproate is another effective anti-seizure drug used in many epilepsy syndromes. It increases brain GABA levels and affects sodium and calcium channels to calm overactive neurons. It is given once or several times daily, with dose carefully titrated based on blood levels. Important side effects include liver toxicity, pancreatitis, weight gain, hair loss, tremor and high risk for birth defects, so liver tests and blood counts are needed and it is used with caution in metabolic disorders.

3. Topiramate (Topamax)
   Topiramate is a broad-spectrum antiepileptic used as add-on or monotherapy for partial and generalised seizures. It blocks voltage-dependent sodium channels, enhances GABA effects and reduces certain glutamate activity, which together dampen seizure activity. It is taken orally once or twice daily, with slow dose increases to reduce side effects such as appetite loss, weight loss, tingling, cognitive slowing, kidney stones and metabolic acidosis. Adequate hydration and regular monitoring are important.

4. Clobazam (Onfi, Sympazan)
   Clobazam is a benzodiazepine-type antiepileptic often used as add-on treatment for severe epilepsies. It enhances GABA-A receptor activity, increasing inhibitory signals in the brain. It is given by mouth once or twice daily, with dose carefully increased to balance benefits and sedation. Side effects can include drowsiness, drooling, behaviour changes, tolerance and dependence, and it can interact with other medicines, so doctors adjust doses cautiously.

5. Midazolam (for emergency seizure control)
   Midazolam is a short-acting benzodiazepine used to stop prolonged seizures or status epilepticus, sometimes by injection or specialised rescue preparations. It acts quickly on GABA-A receptors to suppress excessive neuronal firing. Dose is weight-based and given by trained staff or caregivers according to clear protocols. Side effects include drowsiness and risk of depressed breathing, so continuous monitoring is essential after use.

6. Omeprazole (Prilosec and generics)
   Omeprazole is a proton pump inhibitor used for gastroesophageal reflux disease (GERD), which is common in neurologically impaired children. It blocks the gastric proton pump in stomach cells, strongly reducing acid production. It is usually taken once daily before a meal, with dose adjusted for age and weight. Side effects may include headache, abdominal pain, diarrhoea, and, with long-term use, possible effects on vitamin/mineral absorption and infection risk.

7. H2 blockers (such as ranitidine alternatives)
   Where available and appropriate, H2 receptor antagonists are sometimes used for milder reflux. They block histamine H2 receptors on stomach cells, lowering acid secretion. They are usually given twice daily. Side effects can include headache, diarrhoea or rarely liver enzyme changes. Due to evolving safety data and withdrawals of some agents, doctors select products and doses based on updated national guidelines rather than older over-the-counter habits.

8. Ondansetron (Zofran and generics)
   Ondansetron is an anti-nausea medicine that blocks 5-HT3 serotonin receptors. It is used for severe vomiting, for example during acute illness or procedures, and may help children with CDG who have recurrent vomiting. It is given by mouth or injection with weight-based dosing and limited number of doses per day. Side effects can include constipation, headache and rare heart rhythm changes, so doctors consider ECG monitoring in high-risk patients.

9. Polyethylene glycol 3350 (PEG; e.g., MiraLAX, PEG preparations)
   Polyethylene glycol 3350 is an osmotic laxative for chronic constipation, a common problem in children with low tone or limited mobility. It is a powder mixed with fluid and taken once daily, with dose adjusted to achieve soft daily stools without diarrhoea. It works by holding water in the stool, softening it and increasing stool frequency. Side effects can include bloating, cramps or diarrhoea if the dose is too high.

10. Electrolyte PEG bowel preparations (Golytely, NuLYTELY, etc.)
    For certain procedures (such as endoscopy) or severe constipation, PEG with electrolytes may be used under close medical supervision. These solutions combine PEG with salts to cleanse the bowel. They are consumed in large volumes over several hours. Mechanistically, they draw water into the bowel, flushing stool. Side effects can include nausea, vomiting, abdominal fullness and electrolyte shifts, so they are not routine everyday laxatives.

11. Baclofen (oral GABA-B agonist)
    Baclofen is a muscle relaxant used for spasticity or severe muscle stiffness. It acts on GABA-B receptors in the spinal cord to reduce excitatory signals to muscles. It is given by mouth several times a day, starting with low doses and slowly increasing. Side effects include sleepiness, low muscle tone, dizziness and risk of withdrawal symptoms if stopped suddenly, so tapering is necessary. In some cases, special formulations or intrathecal baclofen pumps are considered by specialists.

12. Analgesics (paracetamol / acetaminophen and ibuprofen)
    Simple pain relief may be needed after procedures or for chronic discomfort. Paracetamol works mainly at central pain pathways and is dosed by weight up to a daily maximum, with liver toxicity risk if overdosed. Non-steroidal drugs like ibuprofen reduce inflammation by blocking COX enzymes, but may irritate the stomach or affect kidneys, so dosing and timing follow paediatric guidelines. In CDG, doctors are particularly careful about liver and kidney function when choosing pain medicines.

13. Antibiotics (various classes)
    Children with COG6-CDG may have recurrent infections due to aspiration, hospital stays or immune issues. Different antibiotics (such as penicillins, cephalosporins or macrolides) are used based on infection type and local resistance patterns. They work by blocking bacterial cell wall synthesis or protein production. Side effects include diarrhoea, allergic reactions and, rarely, serious organ toxicity. Overuse can cause resistance, so doctors prescribe them only when clearly needed.

14. Bronchodilators (e.g., salbutamol / albuterol)
    In children with reactive airways or lung disease, inhaled bronchodilators may be used. These medicines stimulate beta-2 receptors in airway smooth muscle, relaxing the muscles and opening the airways. They are delivered by inhaler or nebuliser, with dose based on age and weight. Side effects include tremor, fast heartbeat and agitation, especially at higher doses. They are usually used as needed for wheeze or under respiratory specialist guidance.

15. Vitamin and mineral supplements (standard preparations)
    Standard vitamin D, calcium, iron, and multivitamin supplements are often used to correct laboratory deficiencies and support bone health and immunity. They work by replacing missing nutrients that the body needs for normal metabolism, blood formation and bone strength. Doses are tailored to age and blood test results to avoid both deficiency and toxicity. Supplements do not treat the COG6 defect but help prevent extra problems like anaemia or rickets.

16. Hormone-replacement therapies (e.g., thyroid or adrenal hormones)
    If endocrine tests show problems like hypothyroidism or adrenal insufficiency, standard hormone-replacement medicines may be used. They work by directly replacing the missing hormone, restoring closer-to-normal metabolism and stress response. Doses are carefully adjusted using blood tests and clinical signs. These drugs are only given when proven hormone deficiency is present; they are not general treatments for COG6-CDG.

17. Antispastic and sedating medicines other than baclofen (e.g., benzodiazepines)
    For severe spasticity, dystonia, or distress, short-term use of medicines such as diazepam may be considered. They enhance GABAergic inhibition in the brain and spinal cord, reducing muscle over-activity and anxiety. They are given at the lowest effective dose for the shortest time due to side effects like sedation, dependence and breathing suppression. Careful specialist oversight is required.

18. Proton pump inhibitor alternatives and mucosal protectants
    In children with stubborn reflux, doctors may combine or switch between acid-suppressing drugs or add mucosal protectants. These work by coating the oesophagus and stomach lining or further reducing acid. Doses and duration depend on symptoms and endoscopy results. Potential side effects include diarrhoea and changes in absorption of nutrients or other medicines, so regular review is needed.

19. Pro-motility agents (where available and appropriate)
    Pro-kinetic drugs are sometimes used in difficult reflux or delayed gastric emptying. They increase movement of the stomach and intestines to help food pass through more quickly. Because of side effects like movement disorders or cardiac risks with some agents, their use is highly restricted and guided by specialist advice and updated safety warnings. They are not routine in every child with CDG.

20. Investigational and compassionate-use therapies
    Research in CDG includes substrate supplements, pharmacological chaperones, repurposed small molecules and gene-based approaches. For COG6-CDG specifically, there is currently no established disease-modifying drug, but future clinical trials may explore such options. Families who consider research participation must do so under recognised ethics-approved studies with detailed informed consent. Investigational treatments should never replace proven supportive care without specialist guidance.

---

Dietary molecular supplements

Evidence for supplements in COG6-CDG is limited; they are usually used to correct measured deficiencies or as supportive care, not as cures.

1. L-carnitine
   L-carnitine helps transport fatty acids into mitochondria for energy production. In some metabolic diseases with low carnitine levels, supplementation can improve energy and reduce fatigue. It is usually given by mouth in divided doses based on weight and blood levels. Side effects can include diarrhoea or fishy body odour. In COG6-CDG it may be considered if tests show deficiency, under metabolic specialist guidance.

2. Coenzyme Q10 (ubiquinone)
   CoQ10 is part of the mitochondrial electron transport chain. Supplementation may support energy metabolism and antioxidant defences, especially if measured levels are low. It is taken orally with fat-containing food to improve absorption; doses vary with age and indication. Side effects are usually mild, such as stomach upset. Evidence in COG6-CDG is extrapolated from other mitochondrial and metabolic disorders.

3. Omega-3 fatty acids (fish oil or algae-based)
   Omega-3 fatty acids influence cell membranes and have anti-inflammatory and neuroprotective effects. Supplements are sometimes used to support brain and eye development and to reduce inflammation. Doses are based on body weight and adjusted to avoid excess calories or bleeding risk. Side effects can include fishy aftertaste or loose stools. Benefits in COG6-CDG are theoretical and should be discussed with clinicians.

4. Vitamin D
   Vitamin D is crucial for bone health, immunity and muscle function. Deficiency is common in children with limited mobility or poor feeding. Supplementation doses are chosen based on blood levels and national guidelines, with regular monitoring to avoid toxicity. Vitamin D works by improving calcium absorption and bone mineralisation. In COG6-CDG it supports general health rather than the core glycosylation problem.

5. Calcium supplements
   Calcium supports bone strength and neuromuscular function. If dietary intake is poor or bone density is low, calcium supplements may be used with vitamin D. Doses are calculated from age, diet and blood levels. Side effects can include constipation or kidney stone risk at high doses. In this setting, calcium helps prevent fractures and bone deformities in non-ambulant children.

6. Iron supplementation
   Anaemia can worsen fatigue and developmental delay. When tests show iron deficiency, oral iron supplements are prescribed with weight-based dosing. Iron supports haemoglobin production and oxygen transport. Side effects include dark stools, constipation or stomach upset. Treating iron deficiency does not change COG6-CDG itself but improves energy, growth and resilience to infection.

7. Multivitamin with trace elements
   A complete multivitamin containing B vitamins, zinc, selenium and other micronutrients may be used when intake is restricted or feeds are specialised. These nutrients act as cofactors in many enzyme reactions. Doses match age recommendations and should not exceed the upper safe limit. A multivitamin helps cover small nutrient gaps that are common in children with chronic illness and feeding issues.

8. Probiotics
   Probiotics are “good bacteria” that may support gut health, especially during or after antibiotic courses. They aim to restore a healthy microbiome, which can improve stool consistency and reduce some gastrointestinal symptoms. Evidence is mixed and strain-specific, so products should be chosen carefully. Side effects are usually mild gas or bloating; severely immunocompromised children need specialist advice before use.

9. Medium-chain triglyceride (MCT) oil
   MCT oil contains shorter fatty acids that are more easily absorbed and metabolised than long-chain fats. It can boost calorie intake for children with poor weight gain. It is added gradually to feeds to avoid diarrhoea. MCTs are absorbed directly into the portal circulation and can be a useful calorie source in some malabsorption settings. Their use in COG6-CDG should be individualised.

10. Branched-chain amino acid–rich supplements
    In children with poor muscle mass, supplements enriched with branched-chain amino acids (leucine, isoleucine, valine) may support muscle protein synthesis. They are provided as part of specialised formulas or modular powders, with doses tailored by dietitians. Side effects can include taste issues or nausea. Evidence in CDG is limited, so these are considered case by case.

---

Immunity-booster, regenerative and stem-cell–related drugs

These therapies are highly specialised and used only when clearly indicated; some are still experimental. They do not replace standard supportive care.

1. Intravenous immunoglobulin (IVIG)
   If COG6-CDG is associated with specific antibody deficiencies, IVIG may be used. It is a pooled antibody product given by infusion at intervals. The purpose is to provide ready-made antibodies to help prevent or treat serious infections. It works by supplementing the patient’s immune system. Side effects include infusion reactions, headache, and rare thrombosis; it is used only when clearly needed and after immunology assessment.

2. Granulocyte colony-stimulating factor (G-CSF, e.g., filgrastim)
   If a child develops severe neutropenia with recurrent bacterial infections, G-CSF may be considered. It is given as subcutaneous injections to stimulate bone marrow production of neutrophils. The purpose is to reduce infection frequency and severity. Mechanistically, it binds receptors on precursor cells, speeding neutrophil maturation. Side effects can include bone pain and temporary spleen enlargement, so careful haematology monitoring is required.

3. Erythropoiesis-stimulating agents (e.g., epoetin alfa)
   For chronic anaemia not correctable with iron alone, erythropoietin analogues can be used. They mimic the natural hormone that signals bone marrow to make red blood cells. Doses are tailored to weight and haemoglobin response. Side effects include hypertension and thrombosis risk. In COG6-CDG, they are reserved for specific haematological indications, not routine therapy.

4. Growth hormone (somatropin) in proven deficiency
   If endocrine testing shows true growth hormone deficiency, standard recombinant growth hormone may be offered. It is given as daily or several-times-weekly injections. It stimulates growth plate cartilage and protein synthesis, promoting linear growth and muscle mass. Side effects can include headache, joint pain and changes in glucose tolerance, so endocrinologists closely monitor treatment. It is not used just because a child is small, but only with documented deficiency.

5. Haematopoietic stem-cell transplantation (HSCT – theoretical / exceptional)
   For some metabolic or immune diseases, HSCT can correct bone-marrow–derived cells. At present there is no standard evidence that HSCT is effective or safe as a routine treatment for COG6-CDG, but it might be discussed in exceptional research settings if specific immune or marrow defects are dominant. HSCT has major risks, including infection, graft-versus-host disease and organ toxicity, so it is only considered in expert centres with very careful risk–benefit analysis.

6. Emerging gene and cell therapies (research only)
   Current reviews of CDG therapies describe experimental approaches like gene therapy, RNA-based methods, pharmacological chaperones and cell-based strategies. For COG6-CDG, these remain in early research stages. The idea is to correct or bypass the underlying genetic error so Golgi glycosylation becomes more normal. Because these methods are still being tested, they should only be accessed through genuine clinical trials or registries, never through unregulated clinics.

---

Surgeries (Procedures and why they are done)

1. Gastrostomy tube insertion (G-tube or PEG tube)
   For children with severe feeding difficulties, poor weight gain, or high aspiration risk, a feeding tube can be placed directly into the stomach through the abdominal wall. The purpose is safe, reliable nutrition and medication delivery. It is usually done under general anaesthesia using endoscopic or surgical techniques. This reduces the struggle of oral feeding, can improve growth, and lowers aspiration risk, though tubes require careful daily care.

2. Fundoplication surgery for severe reflux
   If reflux remains severe despite medicines and positioning, a fundoplication may be considered. In this surgery, the top of the stomach is wrapped around the lower oesophagus to strengthen the valve and reduce acid backflow. The purpose is to reduce vomiting, oesophagitis and aspiration. It is usually done laparoscopically. Possible complications include gas bloat, difficulty belching and surgical risks, so it is reserved for the most severe cases.

3. Orthopaedic surgery for contractures or scoliosis
   Severe joint contractures or spinal curvature can interfere with sitting, care and breathing. Orthopaedic surgery may lengthen tight tendons, release contractures or correct scoliosis with rods. The purpose is better posture, comfort and hygiene. It works by physically re-aligning bones and soft tissues. Intensive physiotherapy before and after surgery is needed to maintain gains and prevent recurrence.

4. Ophthalmologic surgery (e.g., strabismus or ptosis repair)
   Some children have eye misalignment (strabismus) or droopy eyelids (ptosis). Eye surgery can reposition eye muscles or lift the eyelid. The purpose is better visual development, appearance and sometimes wider visual field. Mechanistically, surgery rebalances muscle forces or tightens eyelid tissues. Post-operative patching or glasses may still be needed for best visual outcomes.

5. Corrective surgery for associated malformations
   Case reports in COG6-CDG describe rare malformations such as recto-vaginal fistula or genital anomalies. These may need specific paediatric surgical repair to restore normal anatomy and function. The purpose is to prevent infections, improve continence and support sexual and reproductive health later in life. Surgery is planned by multidisciplinary teams, considering overall health and anaesthetic risks.

---

Prevention and lifestyle measures

1. Genetic counselling before future pregnancies – Carrier testing and discussion of options (prenatal diagnosis, preimplantation genetic testing where available) can reduce recurrence risk or prepare families for intensive care needs.

2. Timely and complete vaccinations – Staying up to date with national immunisation schedules reduces the risk of serious infections in a medically fragile child.

3. Regular growth and nutrition monitoring – Frequent checks of weight, length/height and feeding help prevent severe malnutrition and catch problems early.

4. Early physiotherapy and positioning – Starting physiotherapy and proper positioning early can prevent joint contractures and scoliosis rather than treating them later.

5. Safe feeding practices – Following swallowing recommendations (texture modifications, slow feeding, correct posture) helps prevent aspiration pneumonia and choking.

6. Routine screening of liver, heart and endocrine function – Periodic blood tests and scans can detect treatable complications like liver disease, cardiomyopathy or hormone problems before they cause severe symptoms.

7. Infection-prevention habits at home – Handwashing, avoiding smoke exposure and quick treatment of minor infections can reduce hospitalisations.

8. Safe home environment – Using supports, rails, and avoiding tripping hazards prevents falls in children with poor balance or seizures.

9. Dental and bone health promotion – Daily toothbrushing, dental check-ups and ensuring vitamin D/calcium intake help prevent dental decay and fractures.

10. Connection with specialist centres and patient groups – Registering with CDG reference centres and family organisations improves access to new knowledge, trials and psychosocial support.

---

When to see doctors

Parents and caregivers of a child with COG6-CDG should maintain regular follow-up with their specialist team, usually every few months in early life. You should seek urgent medical attention for prolonged seizures, any episode of breathing difficulty, persistent vomiting with dehydration signs (dry mouth, no urine, sleepiness), high fever with lethargy, sudden change in consciousness, or signs of severe pain. You should also contact the team promptly if feeding worsens, weight drops, new movement problems appear or behaviour changes significantly, as these may indicate treatable complications.

---

What to eat and what to avoid

1. Aim for a balanced, high-energy diet – Use energy-dense foods (oils, nut butters if safe, full-fat dairy or prescribed formulas) to support growth, as many children have increased energy needs and feeding fatigue.

2. Use texture-modified foods if swallowing is unsafe – Purees, mashed foods and thickened liquids can lower choking risk, according to speech therapist advice. Avoid hard, dry or stringy textures if the child coughs or chokes on them.

3. Prefer small, frequent meals – Many children tolerate smaller volumes better, reducing reflux and vomiting compared with large meals.

4. Ensure adequate protein – Include suitable protein sources (meat, fish, eggs, pulses, dairy or specialised formulas) to support muscle and organ repair, within any specific dietary restrictions advised by the metabolic team.

5. Encourage fibre and fluids to prevent constipation – Fruits, vegetables and whole grains (or fibre-enriched formulas) plus sufficient water can support bowel regularity alongside or instead of laxatives, if swallowing is safe.

6. Avoid very salty, very sugary or ultra-processed foods – These offer poor nutrition and may worsen reflux, weight gain pattern or metabolic stress. Healthier, minimally processed options are preferred wherever possible.

7. Limit foods that trigger reflux – For some children, acidic, spicy or very fatty meals increase regurgitation or discomfort. Keeping a food-symptom diary helps identify and avoid personal triggers.

8. Avoid choking-risk foods – Whole nuts, popcorn, hard sweets and raw hard vegetables are risky if chewing or swallowing is weak. Safer alternatives include smooth nut butters and cooked soft vegetables.

9. Avoid unpasteurised and high-risk raw foods – To reduce infection risk, avoid unpasteurised milk, raw eggs and undercooked meats, especially if immunity is weak.

10. Follow individual dietician and metabolic advice – Because COG6-CDG is rare and each child is different, personalised diet plans from the metabolic dietitian always override general suggestions. Families should never start major diets (like ketogenic or fasting-type regimens) without expert supervision.

---

Frequently asked questions (FAQs)

1. Is COG6-CDG curable?
   At present, COG6-CDG is not curable. There is no approved medicine that fixes the COG6 gene or fully corrects glycosylation. Treatment focuses on managing symptoms, preventing complications and supporting development. Research into gene-based and other disease-modifying therapies for CDG is ongoing, but remains experimental.

2. How is COG6-CDG inherited?
   COG6-CDG follows an autosomal recessive pattern. This means a child is affected when they receive one non-working COG6 gene from each parent. Parents are usually healthy carriers. Each pregnancy between two carriers has a 25% chance of an affected child, a 50% chance of a carrier child and a 25% chance of a child with two working copies.

3. At what age do symptoms usually appear?
   Symptoms typically start in infancy, often with feeding problems, poor weight gain, low muscle tone and developmental delay. Some features, like skeletal abnormalities or hormone problems, may become clearer later. Because this disease is ultra-rare, the exact age and pattern vary widely between children.

4. What tests confirm the diagnosis?
   Diagnosis usually involves a combination of clinical evaluation, specialised blood tests for glycosylation patterns, and genetic testing that identifies pathogenic variants in the COG6 gene. Sometimes skin or other tissue studies of glycosylation are used. Genetic testing of parents can confirm carrier status.

5. Why are there no specific COG6-targeted medicines yet?
   COG6-CDG affects complex intracellular trafficking and glycosylation, which is hard to correct with simple drugs. Because the disease is extremely rare, running large clinical trials is challenging. Current research is exploring ways to rescue or bypass defective glycosylation, but these approaches must be carefully tested for safety before routine use.

6. Can diet alone treat COG6-CDG?
   No specific diet has been proven to correct the underlying glycosylation defect in COG6-CDG. However, careful nutritional support can improve growth, strength, immunity and comfort, which strongly affects quality of life. Diet is therefore an important supportive treatment, but not a cure.

7. Will my child always have developmental delays?
   Most reported children with COG6-CDG do have significant developmental delays or intellectual disability, although the severity varies. Early therapies, good seizure control, nutrition and supportive education can help each child reach their personal best, but it is unlikely that development will be completely typical.

8. What is the role of seizure medicines in this condition?
   Seizures are common in many CDGs, including COG6-CDG. Anti-seizure medicines such as levetiracetam, valproate, topiramate and clobazam can reduce seizure frequency and severity, which improves safety and can support development. Medicine choice and dosing are highly individual and based on EEG patterns, side-effect profiles and other health issues.

9. Can my child have routine surgeries and anaesthesia?
   Many children with CDGs safely undergo surgeries such as gastrostomy insertion or orthopaedic procedures. However, anaesthesia risks may be higher because of muscle weakness, seizures, heart or liver problems. It is important that anaesthetists and surgeons review the diagnosis, current medicines and recent investigations in advance and plan careful peri-operative monitoring.

10. Does COG6-CDG affect life expectancy?
    In severe cases, COG6-CDG can be life-limiting, especially when there are serious infections, organ failure or uncontrolled seizures in early life. Some individuals survive into later childhood or beyond. Because so few patients are known, predicting life expectancy for a single child is very difficult. The care team can discuss prognosis based on that child’s specific situation.

11. Should brothers and sisters be tested?
    Testing of siblings is usually recommended if there is a confirmed family mutation, especially for newborns or young children who might benefit from early monitoring and support. Genetic counsellors can explain the benefits and limitations of testing, respect family preferences, and organise testing pathways.

12. Can adults have COG6-CDG?
    Most reported cases are in children, and some individuals do not survive into adulthood. However, milder or undiagnosed cases could reach adult age. Adult patients may present with a mix of neurological, endocrine and skeletal problems. As genetic testing becomes more common, more older individuals with mild CDG forms are being recognised.

13. What research or clinical trials exist?
    International CDG networks and rare-disease registries collect data and support clinical trials for CDGs in general. Trials may focus on biomarkers, natural history, symptomatic drugs or new gene-based approaches. Families can ask their metabolic specialist or CDG patient organisations about ongoing studies and whether their child might be eligible.

14. How can families cope emotionally and practically?
    Connecting with other families through CDG support groups, seeking counselling, and working with social services for equipment, transport and financial help can ease the burden. Clear communication with the care team and written care plans also reduce stress. Everyone in the family, including siblings, may need emotional support at different times.

15. What is the most important thing parents can do?
    Parents are central members of the care team. Learning about the condition, keeping records, sharing observations, and advocating for their child’s needs make a major difference. At the same time, looking after their own health and wellbeing is essential. Building a trusted partnership with specialists and therapists helps ensure that care remains realistic, compassionate and centred on the child’s quality of life.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: February 03, 2025.